Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis.
Tomas Kalincik, Sifat Sharmin, Izanne Roos...
https://pubmed.ncbi.nlm.nih.gov/40755195/Actively Recruiting
Led by Imperial College London · Updated on 2026-10-27
2000
Participants Needed
3
Research Sites
N/A
Total Duration
Multiple sclerosis MS is a disease where the immune system harms the brain and spinal cord. Treatments called disease-modifying therapies can help reduce inflammation and disease activity. For some adults with highly active MS, autologous haematopoietic stem cell transplantation AHSCT, which uses a persons own blood-forming stem cells after immune-suppressing treatment, may be an option. Researchers are comparing the long-term safety and effectiveness of AHSCT against high-efficacy disease-modifying therapies H-DMTs such as alemtuzumab, cladribine, natalizumab, and anti-CD20 antibody treatments in this observational study. The study collects information from routine clinical care without assigning or administering treatments. It includes adults with MS treated with either AHSCT or eligible H-DMTs during regular care. The research involves both retrospective data from patients treated between 2008 and 2025 and a prospective phase starting in October 2026 to gather ongoing clinical data. Data include demographics, treatment and relapse history, disability assessments, MRI findings, laboratory results, and safety events, all collected through standardized electronic forms. Participants continue their usual medical care while researchers gather data from clinical records. The study will analyze outcomes such as no evidence of disease activity, relapse rates, MRI activity, disability progression or improvement, treatment changes, serious adverse events, and mortality over up to 24 years. Data quality is ensured through validation checks, and privacy is maintained by pseudonymizing information. No extra treatments or visits are required for research purposes, and safety outcomes are monitored from routine data where available.
CONDITIONS
REAL-MS: Observational Database Study of AHSCT and MS Therapies
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Imperial College London
Lead Sponsor
Imperial College Healthcare NHS Trust
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (may be combined with enrollment)
Duration - Up to 24 years
Participant data from routine clinical care, including treatment history, clinical assessments, MRI results, and safety events, are collected retrospectively and prospectively without extra visits or treatments.
Routine clinical visits as per usual care
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Tomas Kalincik, Sifat Sharmin, Izanne Roos...
https://pubmed.ncbi.nlm.nih.gov/40755195/Christina Zhukovsky, Sofia Sandgren, Thomas Silfverberg...
https://pubmed.ncbi.nlm.nih.gov/33106366/Giovanni L Mancardi, Maria P Sormani, Francesca Gualandi...
https://pubmed.ncbi.nlm.nih.gov/25672923/G Boffa, C Lapucci, E Sbragia...
https://pubmed.ncbi.nlm.nih.gov/32418281/Tomas Kalincik, Sifat Sharmin, Izanne Roos...
https://pubmed.ncbi.nlm.nih.gov/37437240/Richard K Burt, Roumen Balabanov, Joachim Burman...
https://pubmed.ncbi.nlm.nih.gov/30644983/Paolo Antonio Muraro, Antonio Zito, Alessio Signori...
https://pubmed.ncbi.nlm.nih.gov/40251896/Paolo A Muraro, Roland Martin, Giovanni Luigi Mancardi...
https://pubmed.ncbi.nlm.nih.gov/28621766/Paolo A Muraro, Alice Mariottini, Raffaella Greco...
https://pubmed.ncbi.nlm.nih.gov/39814869/Imperial College London
Lead Sponsor
Imperial College Healthcare NHS Trust
Collaborating Sponsor